Glenmark Pharma soars to 52-week high on positive management commentary
Glenmark Pharma soared as managements bullish FY25 targets offset weak quarterly earnings. Despite widening losses due to impairment charges, adjusted net profit nearly tripled, driven by a stake sale in Glenmark Life Sciences.
Glenmark Monroe Glenmark Pharma Us Department Of Justice Settlement Drug Administration Glenmark Life Sciences Glenmark Specialty
Source: moneycontrol.com